Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis : a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib
Hochberg, Marc C. (University of Maryland School of Medicine)
Martel-Pelletier, Johanne (Centre hospitalier de l'Université de Montréal)
Monfort, Jordi (Institut Hospital del Mar d'Investigacions Mèdiques)
Möller, Ingrid (Institut Poal de Reumatologia)
Castillo, Juan Ramón (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Arden, N. K (University of Oxford. Medical Science Division)
Berenbaum, Francis (Sorbonne University)
Blanco-García, F.J (Instituto de Investigación Biomédica de A Coruña)
Conaghan, Philip G. (Leeds Institute of Rheumatic and Musculoskeletal Medicine)
Domènech Carbó, Gemma (Universitat Autònoma de Barcelona. Facultat de Medicina)
Henrotin, Yves (Université de Liège. Faculté de Médecine. Unité de Recherche sur l'Os et le Cartilage)
Pap, Thomas (Universitätsklinikum Münster. Institut für Muskuloskelettale Medizin)
Richette, Pascal (Université Paris-Diderot)
Sawitzke, Allen (University of Utah School of Medicine)
du Souich, Patrick (Université de Montréal. Département de pharmacologie et physiologie)
Pelletier, Jean-Pierre (Centre de recherche du Centre hospitalier de l'Universite de Montreal)

Fecha:	2015
Resumen:	To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain. Double-blind Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES) conducted in France, Germany, Poland and Spain evaluating treatment with CS+GH versus celecoxib in 606 patients with Kellgren and Lawrence grades 2-3 knee osteoarthritis and moderate-to-severe pain (Western Ontario and McMaster osteoarthritis index (WOMAC) score ≥301; 0-500 scale). Patients were randomised to receive 400 mg CS plus 500 mg GH three times a day or 200 mg celecoxib every day for 6 months. The primary outcome was the mean decrease in WOMAC pain from baseline to 6 months. Secondary outcomes included WOMAC function and stiffness, visual analogue scale for pain, presence of joint swelling/effusion, rescue medication consumption, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria and EuroQoL-5D. The adjusted mean change (95% CI) in WOMAC pain was −185. 7 (−200. 3 to −171. 1) (50. 1% decrease) with CS+GH and −186. 8 (−201. 7 to −171. 9) (50. 2% decrease) with celecoxib, meeting the non-inferiority margin of −40: −1. 11 (−22. 0 to 19. 8; p=0. 92). All sensitivity analyses were consistent with that result. At 6 months, 79. 7% of patients in the combination group and 79. 2% in the celecoxib group fulfilled OMERACT-OARSI criteria. Both groups elicited a reduction >50% in the presence of joint swelling; a similar reduction was seen for effusion. No differences were observed for the other secondary outcomes. Adverse events were low and similarly distributed between groups. CS+GH has comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile. NCT01425853.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Analgesics ; NSAIDs ; Osteoarthritis
Publicado en:	Annals of the rheumatic diseases, Vol. 75, issue 1 (Jan. 2016) , p. 37-44, ISSN 1468-2060

DOI: 10.1136/annrheumdis-2014-206792
PMID: 25589511

8 p, 1.6 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados